Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile
11. April 2019 10:00 ET
|
Immuron Limited
C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues...
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé
31. Januar 2019 02:00 ET
|
Deinove
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé Le design de l’essai a été optimisé pour maximiser les chances de démontrer...
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
31. Januar 2019 02:00 ET
|
Deinove
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in...
Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)
31. Januar 2018 09:30 ET
|
Immuron Limited
Key Highlights: First patients enrolled in Immuron’s IMM-529 clinical study at Hadassah Medical Center in Israel Trial will treat 60 confirmed patients over 28 days to evaluate safety and efficacy of...
SteraMist™ Contributes to Substantial Reduction in Clostridium Difficile Burden in Hospital
03. April 2017 16:05 ET
|
TOMI Environmental Solutions, Inc.
BEVERLY HILLS, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination and infection prevention company that specializes in...
Paratek Presents Data from Omadacycline Clinical Development Program at ECCMID
11. April 2016 07:30 ET
|
Paratek Pharmaceuticals
Pooled analysis from Phase 2 and truncated Phase 3 studies demonstrates comparable safety and efficacy profiles for omadacycline compared with linezolid Single dose randomized trial...
Paratek Presents Pre-Clinical Data on the Effects of Omadacycline on Clostridium Difficile
11. April 2016 07:30 ET
|
Paratek Pharmaceuticals
AMSTERDAM, Netherlands, April 11, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today presented data from two pre-clinical studies evaluating the impact of omadacycline on...
C. difficile Infection Increases Hospital Costs by 40 Percent Per Case, Study Finds
10. Dezember 2015 09:27 ET
|
Premier, Inc.
Patients with C. diff stay in hospital 55 percent longer and are 77 percent more likely to be readmitted CHARLOTTE, N.C., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Clostridium difficile (C. diff),...
Fecal transplant pills: Large-scale production begins
28. Oktober 2015 08:39 ET
|
OpenBiome
BOSTON, Oct. 28, 2015 (GLOBE NEWSWIRE) -- A new pill created by a team of MIT-trained researchers provides fecal transplant therapy without requiring the traditional, more invasive stool delivery...
Stellar Biotechnologies to Present at the 26th Annual ROTH Capital Growth Conference
27. Februar 2014 09:05 ET
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwired - Feb 27, 2014) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), a company focused in the immunotherapy arena with...